Breathe Well Live Well
|
Asthma and COPD Therapies Market Forecast 2015-2025
PR Newswire (press release) What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. |
View full post on asthma – Google News
Conditions: Asthma (Part 1); COPD (Part 2)
Interventions: Drug: Dose 1, AZD8871 50 ?g (Part 1); Drug: Dose 2, AZD8871 100 ?g (Part 1); Drug: Dose 3, AZD8871 300 ?g (Part 1); Drug: Dose 4, AZD8871 600 µg (Part 1); Drug: Dose 5, AZD8871 1200 µg (Part 1); Drug: Dose 6, AZD8871 1800 ?g (Part 1); Drug: Placebo, AZD8871 placebo (Part 1); Drug: Treatment A, AZD8871 dose A (Part 2); Drug: Treatment B, AZD8871 dose B (Part 2); Drug: Treatment C, Indacaterol 150 ?g (Part 2); Drug: Treatment D, Tiotropium 18 ?g (Part 2)
Sponsor: AstraZeneca
Not yet recruiting – verified October 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
freshwatercleveland |
SpiroSano helps patients, doctors manage conditions like asthma and COPD
freshwatercleveland SpiroSano has developed a system to track and manage data related to respiratory conditions such as asthma, COPD and cystic fibrosis. The data can be tracked using any medical device, such as an inhaler, with any mobile device. “The goal is to improve … |
View full post on asthma – Google News
|
Research and Markets: Global Asthma & COPD Market Report: 2015 Edition …
Business Wire (press release) The leading players operating in the industry include AstraZeneca, Merck and Co., Roche, Sanofi and Novartis which are also profiled in this report. The present report provides a comprehensive analysis of the global asthma & COPD market with focus on … |
View full post on asthma – Google News
|
Asthma, COPD Therapies Raise Curtain at Conference
Medscape AMSTERDAM — Personalized medicine will be a key theme here at the European Respiratory Society (ERS) International Congress 2015, especially for complicated diseases like asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung … |
View full post on asthma – Google News
|
Asthma and COPD Drug Market is expected to reach USD 12619.8 million in 2017
Medgadget.com (blog) According to the new report published by Transparency Market Research “Asthma and COPD Drug Market – Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 – 2017”, the global asthma and COPD market was worth USD … |
View full post on asthma – Google News
MD Magazine |
Asthma, COPD Sometimes Overlap, Specialists Say
MD Magazine Specialists agree that a condition unofficially known as asthma-COPD overlap syndrome (ACOS) exists, according to a survey completed by Marc Miravitlles, MD, and colleagues. The participants were 26 specialists in either asthma or chronic obstructive … |
View full post on asthma – Google News
Condition: Pulmonary Disease, Chronic Obstructive
Intervention:
Sponsors: Portsmouth Hospitals NHS Trust; Pfizer
Not yet recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Asthma and COPD Market Set to Grow Leading to Surge in Demand for Combination …
PR Newswire (press release) Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated – Asthma and COPD – both of which … |
View full post on asthma – Google News
iMedicalApps |
What Propeller Health's new FDA clearance actually means for managing COPD and …
iMedicalApps In 2013, iMedicalapps reported on the introduction of Propeller Health's inhaler sensor, which allows patients with asthma and COPD to record the time and place that they use their medication. The device sits on top of a standard metered dose inhaler … |
View full post on asthma – Google News